Prosecution Insights
Last updated: April 19, 2026
Application No. 17/778,806

SILICONE-BASED COMPOSITION AND CURED PRODUCT THEREOF

Final Rejection §103
Filed
Sep 22, 2022
Examiner
ZIMMER, MARC S
Art Unit
1765
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Momentive Performance Materials Korea Co. Ltd.
OA Round
4 (Final)
79%
Grant Probability
Favorable
5-6
OA Rounds
2y 7m
To Grant
95%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allow Rate
1230 granted / 1549 resolved
+14.4% vs TC avg
Strong +16% interview lift
Without
With
+15.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
48 currently pending
Career history
1597
Total Applications
across all art units

Statute-Specific Performance

§101
0.3%
-39.7% vs TC avg
§103
39.2%
-0.8% vs TC avg
§102
27.7%
-12.3% vs TC avg
§112
24.2%
-15.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1549 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1, 3, 5, 9-10, and 12, and 14-16 are rejected under 35 U.S.C. 103 as being unpatentable over Lin et al., U.S. Patent # 6,627,672 for the reasons outlined previously, and in view of the following additional consideration(s). Apparently having observed that the amount of tin catalyst reported in the exemplifications summarized in Table 1 is 0.4 wt.%, Applicant has narrowed the range of suitable quantities of this component to 0.07% to 0.35%. As an initial matter, the current record doesn’t reflect that there is anything particularly critical with a maximum amount of .35%. Indeed, how could it when original claim 7 allowed it to be as much as 0.5%? In this regard, the Examiner reminds Applicant of the Titanium Metals Corp. of America v. Banner, 778 F.2d 775, 227 USPQ 773 (Fed. Cir. 1985) decision which held that, “a prima facie case of obviousness exists where the claimed ranges and prior art ranges do not overlap but are close enough that one skilled in the art would have expected [the claimed product and a product disclosed in the prior art] to have the same properties.” Moreover, acceptable quantities of a tin catalyst are assuredly not limited to this exact value mentioned in Table 1 and one of ordinary skill in the art of formulating moisture/condensation-curable organopolysiloxane compositions is capable of determining suitable amounts of a catalyst (undoubtedly a result-effective variable) as a matter of routine experimentation. The same goes for a suitable amount of the titanium catalyst. It is widely documented that titanium catalysts, while themselves effective promoters of condensation curing reactions, exhibit less activity than do their tin-based counterparts and, therefore, it would be obvious that more of a titanate must be employed in this capacity. (See, as one document that teaches the lower activity of titanium catalysts, [0004] of U.S. 2022/0162393.) As with the tin catalyst candidates, one of ordinary skill is able to ascertain acceptable quantities of a titanate catalyst as a matter of routine experimentation. “Discovering an optimum value of a result effective variable involves only routine skill in the art.” In re Boesch, 617 F.2d 272, 205 USPQ 215 (CCPA 1980). Claim 11 is rejected under 35 U.S.C. 103 as being unpatentable over Lin et al., U.S. Patent # 6,627,672 in view of Levandoski et al., U.S. Patent # 6,140,444 for the reasons outlined previously. Response to Arguments The Examiner continues to maintain that the rejection should be withdrawn predicated on the notion that they have demonstrated embodiments of the base polymer of the claimed invention that contain acrylate groups to exhibit superior “process development” rates. Again, notwithstanding the fact that a methacrylate-terminated congener is disclosed in Table 1 of Lin, the Examiner still regards the acrylate-terminated polymers to be anticipated for reasons articulated before. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARC S ZIMMER whose telephone number is (571)272-1096. The examiner can normally be reached M-F 8:30-5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Heidi Kelley can be reached at 571-270-1831. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. December 23, 2025 /MARC S ZIMMER/Primary Patent Examiner, Art Unit 1765
Read full office action

Prosecution Timeline

Sep 22, 2022
Application Filed
Apr 15, 2025
Non-Final Rejection — §103
Jun 25, 2025
Response Filed
Jul 01, 2025
Final Rejection — §103
Aug 29, 2025
Response after Non-Final Action
Sep 08, 2025
Non-Final Rejection — §103
Dec 11, 2025
Response Filed
Dec 23, 2025
Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600882
SILICONE COMPOSITIONS CONTAINING ACRYLATE CURE ACCELERATOR
2y 5m to grant Granted Apr 14, 2026
Patent 12590186
FLUOROSILICONE POLYMERS, COMPOSITIONS, AND USES THEREOF
2y 5m to grant Granted Mar 31, 2026
Patent 12583209
MULTILAYER BODY COMPOSED OF CURED ORGANOPOLYSILOXANE FILMS, USE OF SAME, AND METHOD FOR PRODUCING SAME
2y 5m to grant Granted Mar 24, 2026
Patent 12584008
POLYOLEFIN COMPOSITION FOR ROOFING APPLICATIONS
2y 5m to grant Granted Mar 24, 2026
Patent 12584053
SILANE FUNCTIONALIZED ROSINS
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

5-6
Expected OA Rounds
79%
Grant Probability
95%
With Interview (+15.6%)
2y 7m
Median Time to Grant
High
PTA Risk
Based on 1549 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month